Heterocyclic Compounds, 3-Ring
"Heterocyclic Compounds, 3-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category.
| Descriptor ID |
D006575
|
| MeSH Number(s) |
D03.633.300
|
| Concept/Terms |
Heterocyclic Compounds, 3-Ring- Heterocyclic Compounds, 3-Ring
- 3-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 3 Ring
- Heterocyclic Cpds, 3 Ring
- Fused Heterocyclic Compounds, Three-Ring
- Fused Heterocyclic Compounds, Three Ring
- Three Ring Heterocyclic Compounds
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 3-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 3-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 3-Ring" by people in this website by year, and whether "Heterocyclic Compounds, 3-Ring" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 3 | 3 | 6 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 5 | 8 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 3 | 5 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterocyclic Compounds, 3-Ring" by people in Profiles.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 Nov 22; 79(5):1258-1261.
-
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol. 2024 Jun 13; 31(6):3342-3349.
-
In women with uncomplicated UTIs, gepotidacin was noninferior to nitrofurantoin for therapeutic response at 10 to 13 d. Ann Intern Med. 2024 06; 177(6):JC67.
-
Dolutegravir-induced neural tube defects in mice are folate responsive. AIDS. 2024 03 15; 38(4):439-446.
-
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi's National HIV Treatment Program. Viruses. 2023 12 23; 16(1).
-
Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023 Jul 01; 42(7):576-581.
-
Two-pore channel blockade by phosphoinositide kinase inhibitors YM201636 and PI-103 determined by a histidine residue near pore-entrance. Commun Biol. 2022 07 23; 5(1):738.
-
Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis. 2021 08 02; 73(3):e580-e586.
-
Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations. Int J Pharm. 2021 Sep 25; 607:120889.
-
Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV. Medicine (Baltimore). 2020 Nov 20; 99(47):e23335.